CVRx Announces New Current Procedural Terminology Category I Codes For Barostim To Treat The Symptoms Of Heart Failure
Portfolio Pulse from Benzinga Newsdesk
CVRx, Inc. announced that the AMA has accepted new CPT Category I codes for its Barostim therapy, which treats heart failure symptoms. This decision is expected to facilitate reimbursement and broaden patient access, with implementation set for January 1, 2026.
October 18, 2024 | 6:21 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CVRx has received approval for new CPT Category I codes for its Barostim therapy, which will enhance reimbursement and patient access, potentially boosting its market position.
The acceptance of new CPT Category I codes is a significant regulatory milestone for CVRx, as it will facilitate reimbursement processes and expand patient access to Barostim therapy. This is likely to enhance CVRx's market position and could positively impact its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100